Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.12.2014 | short review

Gene signature profiling of gynaecological malignancies

verfasst von: Peter Horak, MD, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Genetic profiling of cancer may lead to a better understanding of its intra- as well as intertumoural heterogeneity as well as targeted, patient-oriented cancer therapy. Due to the recent advances in molecular biology, important steps towards this goal have been accomplished. Among others, several large profiling analyses of gynaecologic malignancies have been completed and published recently. Most notably, these comprehensive molecular analyses expose a high degree of cancer complexity and heterogeneity. Integration of this data into clinical practice will result in new tumour classifications and possibly change our understanding of cancer pathogenesis and thus necessitate the development of novel diagnostic and therapeutic algorithms.
Vorheriger Artikel Melanoma 2014—an update
Literatur
1.
Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC. Physicians’ attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014;32(13):1317–23. doi:10.1200/JCO.2013.52.4298.CrossRef
2.
Gampenrieder S, Rinnerthaler G, Greil R. Multi-gene signatures in breast cancer: actual clinical impact. Memo. 2014;7(1):16–21.CrossRef
3.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2008;61(2):69–90. doi:10.3322/caac.20107.CrossRef
4.
Bast RC, Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415–28. doi:10.1038/nrc2644.PubMedCentralPubMedCrossRef
5.
Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005;65(22):10602–12. doi:10.1158/0008-5472.CAN-05-2240.PubMedCrossRef
6.
Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11(18):6422–30. doi:10.1158/1078-0432.CCR-05-0508.PubMedCrossRef
7.
8.
Kim J, Coffey DM, Creighton CJ, et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A. 2012;109(10):3921–6. doi:10.1073/pnas.1117135109.PubMedCentralPubMedCrossRef
9.
Darcy KM, Birrer MJ. Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol. 2010;117(3):429–39. doi:10.1016/j.ygyno.2010.01.048.PubMedCentralPubMedCrossRef
10.
Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol. 2008;5(10):577–87. doi:10.1038/ncponc1178.PubMedCrossRef
11.
Bolton KL, Tyrer J, Song H, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010;42(10):880–4. doi:10.1038/ng.666.PubMedCentralPubMedCrossRef
12.
TCGA. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15. doi:nature10166.CrossRef
13.
Verhaak RG, Tamayo P, Yang JY, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013;123(1):517–25.PubMedCentralPubMed
14.
Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi33–8. doi:10.1093/annonc/mdt353.
15.
16.
Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. doi:10.1038/nature12113.PubMedCrossRef
17.
Huang L, Zheng M, Zhou QM, et al. Identification of a gene-expression signature for predicting lymph node metastasis in patients with early stage cervical carcinoma. Cancer. 2011;117(15):3363–73. doi:10.1002/cncr.25870.PubMedCrossRef
18.
Martin CM, Astbury K, McEvoy L, et al. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy. Methods Mol Biol. 2009;511:333–59. doi:10.1007/978-1-59745-447-6_15.PubMedCrossRef
19.
Santin AD, Zhan F, Bignotti E, et al. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology. 2005;331(2):269–91. doi:10.1016/j.virol.2004.09.045.PubMedCrossRef
20.
Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol. 2009;112(2):293–9.PubMedCentralPubMedCrossRef
21.
Bachtiary B, Boutros PC, Pintilie M, et al. Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin Cancer Res. 2006;12(19):5632–40. doi:10.1158/1078-0432.CCR-06-0357.PubMedCrossRef
22.
Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463(7278):191–6. doi:10.1038/nature08658.PubMedCentralPubMedCrossRef
23.
Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21. doi:10.1038/nature12477.
24.
25.
Shrager J, Tenenbaum JM. Rapid learning for precision oncology. Nat Rev Clin Oncol. 2014;11(2):109–18. doi:10.1038/nrclinonc.2013.244.PubMedCrossRef
Metadaten
Titel
Gene signature profiling of gynaecological malignancies
verfasst von
Peter Horak, MD, PhD
Publikationsdatum
01.12.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0177-1

Weitere Artikel der Ausgabe 4/2014

International MDS Working Groups: a model of success to improve diagnosis and treatment in rare diseases: 10-year jubilee of the Austrian MDS platform

  • editorial

Towards automation of flow cytometric analysis for quality-assured follow-up assessment to guide curative therapy for acute lymphoblastic leukaemia in children

  • special report

Melanoma 2014—an update

  • short review

Latest developments in the treatment of metastatic colorectal cancer: update ASCO 2014

  • short review

ASCO 2014: news, hopes, hypes?

  • editorial

Lung cancer: ASCO 2014 update

  • short review